Apimeds Pharmaceuticals (APUS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing Apitox, a bee venom-based biologic for osteoarthritis (OA) and multiple sclerosis (MS).

• Apitox is licensed for US development from Apimeds Korea, which markets a similar product in South Korea.

• No US product revenue to date; business model relies on clinical development, regulatory approval, and future commercialization.

• Plans to outsource manufacturing and pursue strategic partnerships for commercialization.

Financial performance and metrics

• No revenue generated as of September 30, 2024; accumulated deficit of $4.08 million.

• Net loss of $1.08 million for the nine months ended September 30, 2024, and $777,694 for the year ended December 31, 2023.

• Cash balance of $26,571 as of September 30, 2024; pro forma as adjusted cash post-offering estimated at $16.15 million.

• Operating expenses primarily driven by R&D and increased general and administrative costs related to pre-IPO activities.

Use of proceeds and capital allocation

• Estimated net proceeds of $16.1 million (or $18.5 million if over-allotment is exercised) at $4.00 per share.

• Proceeds to fund Phase III clinical trial in knee OA, initiate at least one MS study, manufacturing, debt repayment, and working capital.

• Approximately $10 million allocated to Phase III OA trial, $1.5 million to MS study, $1 million to manufacturing, and $0.7 million to debt repayment.

• Remaining funds for general corporate purposes and potential strategic investments.